Metformin Hydrochloride Teva (Metformin)

Metformin reduces the liver’s production of glucose, decreases the absorption of glucose from the intestine, and enhances the responsiveness of muscle and fat cells to insulin. These actions collectively lower fasting and post‑prandial blood glucose levels without directly stimulating insulin secretion.

The appropriate dose of Metformin Hydrochloride Teva is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of metformin in pregnancy and lactation has not been definitively established. Healthcare providers may weigh potential benefits against possible risks on a case‑by‑case basis. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin is often preferred as first‑line therapy because it does not cause weight gain and has a low risk of hypoglycaemia when used alone. Compared with sulfonylureas, it works by improving insulin sensitivity rather than stimulating insulin release, and it has a well‑documented cardiovascular safety profile.

Metformin Hydrochloride Teva should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

The most serious risk is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or conditions causing hypoxia. Prompt medical attention is required if symptoms such as unexplained fatigue, rapid breathing, or abdominal pain develop.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, or those who have received iodinated contrast media within the previous 48 hours. Clinicians should evaluate each patient’s medical history before prescribing.